BioSpace News Archive

BIOPHYTIS SA announces the approval by a very large majority of all resolutions falling within the remit of the Combined General Meeting.

Insmed Incorporated announced that it priced a registered underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $25.00 per share before deducting underwriting discounts and commissions, and a registered underwritten public offering of $500 million aggregate principal amount of its 0.75% convertible senior notes due 2028.